

腸管ベーチェット病の治療においては、腹部症状や腸管外症状の消失とともに可能な限り CRP の陰性化を目標とする。長期的には腸管機能障害への進展、頻回の外科手術を回避することが重要である。

治療

A. 標準治療

1. 腹痛、下痢、下血などの消化器症状および全身症状の強い場合、内視鏡や X 線造影で深掘れの潰瘍が確認された場合、寛解導入療法として副腎皮質ステロイド薬の投与を考慮する。プレドニゾン換算 0.5mg~1.0mg/kg/day の初期投与量を 1~2 週間継続し、改善があれば週 5mg ぐらいずつ漸減し可能な限り中止する。あるいは寛解導入療法としてインフリキシマブ 5mg/kg を点滴静注で 0、2、6 週の 3 回投与を行う。有効例についてはその後 8 週毎の維持投与へ移行する（投与方法の詳細はクローン病に順ずる。保険未承認）。なお軽~中等症では 5-ASA 製剤が寛解導入に有効な場合がある。
2. 症状が軽快した場合は、維持療法として 5-ASA 製剤やコルヒチンを使用してもよい。5-ASA 製剤の投与量はメサラジン 2.25g~4.0g/day、あるいはサラゾスルファピリジン 3~4g/day とする。
3. 副腎皮質ステロイド薬やインフリキシマブによる治療に抵抗する場合、ステロイド薬を漸減中に症状が再燃する場合はアザチオプリン（初期投与量として 25-50mg/日）などの免疫調節薬^{※7}の投与を考慮する。アザチオプリンの使用にあたっては白血球減少症や肝機能障害などの副作用をモニタリングする必要がある。
4. 完全静脈栄養療法は発熱などの全身症状が強く、狭窄、瘻孔、出血などを伴う例、穿孔の危険が高いと判断される例、高度の口腔・上部消化管病変により継続して経口摂取困難な例、薬物治療抵抗例などの急性期に短期間用いる。長期間のカテーテル留置は敗血症や血栓症のリスクになることも考慮すべきである。完全静脈栄養療法や絶食にて症状の改善が得られた例では経腸栄養療法への移行を考慮してもよい。
5. 成分栄養剤を用いた経腸栄養療法は寛解導入に有効な場合がある。とくに薬物治療抵抗例や重症度の高い例、狭窄など消化管障害の強い例で適応となる。なお経腸栄養療法を行う際には患者の受容性や QOL に配慮する。
6. 外科治療は内科治療で改善が期待できない病態に適応がある。高度の狭窄、穿孔、膿瘍形成、大量出血をきたす症例では絶対適応であり、内科的治療に抵抗する難治例、瘻孔の合併などにより著しく QOL が低下した症例は相対的適応となる。腸管切除を行う場合には、切除範囲が最小限となるようにする。
7. 術後再発の頻度は、とくに噴火口様の深い潰瘍病変を呈した症例と穿孔や瘻孔を合併した症例で高く、吻合部付近に好発する。術後再発予防に有効な治療法はいまだ確立されていないが、原病の再発率が高く複数回の外科治療の可能性のあることを踏まえ、5-ASA 製剤、免疫調節薬、メトロニダゾール、インフリキシマブなどの薬物療法や経腸栄養療法などの治療を考慮してもよい。
8. 眼病変を有するベーチェット病症例では眼科医と治療方針を調整すべきである。

B. オプション治療

*潰瘍病変に対して内視鏡下エタノール散布が有効とする報告があり、特に薬物療法抵抗例では考慮しても良い。

* 関節炎（特に末梢性関節炎）を認める症例では抗リウマチ薬としての効果を期待して、メサラジンからスルファピリジンを含むサラゾスルファピリジンへの変更を考慮してもよい。

補填

※1 Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Igarashi M, Iizuka BE, Matsuda T, Matsui T, Matsumoto T, Sugita A, Takeno M, Hibi T. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol. 42(9):737-45, 2007.

※2 石ヶ坪良明. 腸管ベーチェット病診療ガイドライン平成 21 年度案 ～コンセンサス・ステートメントに基づく～ 厚生労働科学研究 難治性疾患克服研究事業 ベーチェット病に関する調査研究(研究代表者 石ヶ坪良明)、平成 22 年 12 月

※3 文献的エビデンスはインフリキシマブによるものが多数を占めているが、現在日本ではアダリムマブの臨床試験が進行中である。

※4 石ヶ坪良明、岳野光洋、菊地弘敏、長堀正和、井上詠、黒沢美智子. 腸管ベーチェット病に対するインフリキシマブ治療の実態. 厚生労働科学研究 難治性疾患克服研究事業 ベーチェット病に関する調査研究(研究代表者 石ヶ坪良明) 平成 23 年度 総括・分担研究報告書(平成 24 年 3 月)、p89-93

※5 典型的肉眼所見(付図 1)

回盲弁は開大し、回腸末端に管腔の約半周を占める卵円形の深掘れ潰瘍を認める。周囲との境界は比較的明瞭である。

※6 ベーチェット病の完全型、不全型の診断は厚生労働省ベーチェット病診断基準(2003 年)に基づく。

※7 アザチオプリン以外の免疫調節薬、6-MP、シクロスポリン、タクロリムス、メトトレキサートの選択を考慮してもよいが、使用経験の豊富な施設、医師に相談すること。また使用に際しては副作用のモニタリングを十分に行うこと。

※8 内視鏡検査、X 線造影検査で腸管ベーチェット病の典型的病変を呈しても、ベーチェット病診断基準を満たさない場合は単純性潰瘍と呼び、腸管ベーチェット病と区別するが、その経過については腸外病変も含めて臨床的観察を要する。


※9 腸管ベーチェット病の画像(特に内視鏡)所見に関しては、多様性や経時的変化の報告があり、非典型例の診断においては、鑑別診断を更に慎重に行う。

※10 病理組織学的所見(付図 2)

非特異的炎症による多様な病変を呈しうるが、深掘れ潰瘍の内面を滲出壊死層、肉芽組織層、線維組織層が取り巻くのが典型像である。これらの 3 層構造は一般に菲薄で、潰瘍底は概して平坦である。リンパ球集簇が形成されても、潰瘍底とその近傍に限局することがクローン病と異なる。まれに類上皮肉芽腫を認めることがある。特異的な粘膜所見はなく、生検による積極的診断は困難である。





※※ 腸管ベアレット・単純性潰瘍コンセンサス・ステートメント改訂ワーキンググループ

久松理一（慶應義塾大学医学部消化器内科）平井郁仁（福岡大筑紫病院消化器内科）松本主之（九州大学病院消化管内科）小林清典（北里大学東病院消化器内科）長堀正和（東京医科歯科大学消化器内科）松下光伸（関西医科大学内科学第3）小林健二（大船中央病院光学診療部）小金井一隆（横浜市立市民病院外科）国崎玲子（横浜市立大学センター病院IBDセンター）岳野光洋（横浜市立大学免疫・血液・呼吸器内科）岸本暢将（聖路加国際病院アレルギー膠原病科）上野文昭（大船中央病院）田中正則（弘前市立病院臨床検査科）事務局 井上 詠（慶應義塾大学医学部消化器内科）



付図 1 典型的肉眼所見

回盲弁は開大し、回腸末端に管腔の約半周を占める卵円形の深掘れ潰瘍を認める。周囲との境界は比較的明瞭である。



付図 2 病理組織学的所見

- a : 初期には粘膜の限局性炎症により浅い潰瘍を形成する。
- b : 次第に深掘れとなり、フラスコ型の潰瘍となる。
- c : 大型化した潰瘍でもその底部は概ね平坦である。
- d : 潰瘍底は滲出壊死層と薄い肉芽組織層が被覆し、線維組織層は目立たないことが多い。
- e : 潰瘍底の3層構造が菲薄なため、固有筋層が浸食されれば穿孔の危険が高まる。
- f : クローン病類似の瘻孔が形成される場合もある。

Ⅷ第 15 回国際ベーチェット病会議

15th International Conference on Behçet's Disease

Period

13th–15th July 2012
(Council :12th July 2012)

Venue

Yokohama Convention Center

President

Yoshiaki Ishigatsubo

Honorary president

Goro Inaba, Shigeaki Ohno, Fumio Kaneko

URL <http://15icbd.jtbcom.co.jp/>

Secretariat



Department of Internal Medicine and Clinical Immunology Yokohama City University
Graduate School of Medicine

3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 Japan

TEL:81-45-787-2628 Fax:81-45-788-8773 E-mail:sec1nai@med.yokohama-cu.ac.jp

Meeting Secretariat

JTB Communications Inc.

3F IK Bldg., 2-24-9, Kamiosaki, Shinagawa-ku, Tokyo, 141-8657 Japan

TEL:81-3-5434-8759 FAX:81-3-5434-8694 E-mail:15icbd@jtbcom.co.jp



TIME TABLE

		8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	
July 12 (Thurs.)	InterContinental Yokohama Grand 3F Atrantico										Executive Meeting & Council Meeting				
July 13 (Fri.)	3F 301 • 302	President's Welcome Speech		Scientific Session 1 Immunology and Genetics 1 Co-chairs : Ahmet Gül Eun-So Lee		Break	Luncheon seminar 1 Kazuhiko Yamamoto Chair : Graham R Wallace		Break	Scientific Session 2 Immunology and Genetics 2 Co-chairs : Kazuya Iwabuchi Miles R Stanford		Special Lecture Daniel L. Kastner Chair : Yoshiaki Ishigatsubo		Banquet in "Pacific" banquet room, InterContinental Yokohama Grand	
	3F 311 • 312					Luncheon seminar 2 Toshifumi Hibi Chair : Ahmet Gül		Break	Behçet's Disease Patients' Circle						
	3F 315	Poster Set up			Poster viewing				Poster Presentation (core time)						
July 14 (Sat.)	3F 301 • 302			Scientific Session 3 Novel treatment (Immunotherapy) Co-chairs : Ignazio Olivieri Jan AM van Laar		Break	Luncheon seminar 3 Shigeaki Ohno Chair : Haner Direskeneli		Break	Scientific Session 4 Neurological and Vascular lesions Co-chairs : Shunsei Hirohata Jorge Crespo		General Assembly			
	3F 311 • 312	Behçet's Disease Patients' Circle			Break	Luncheon seminar 4 Masataka Kuwana Chair : Noboru Suzuki		Break	Behçet's Disease Patients' Circle				Scientific session 5 Assessment of disease activity (Epidemiology) Co-chairs : Fumio Kaneko Dongsik Bang		
	3F 315	Poster viewing					Poster Presentation (core time)								
July 15 (Sun.)	3F 313 • 314	Scientific Session 6 Ocular and mucocutaneous lesions Co-chairs : Gonca Mumcu Hyeong-Gon Yu		Scientific Session 7 Intestinal lesions Co-chairs : Mamoru Watanabe Gülen Hatemi		Closing Remarks									
	3F 311 • 312	Behçet's Disease Patients' Circle													
	3F 315	Poster viewing			Poster Removal										



SCIENTIFIC PROGRAM

Friday, July 13

8:00 – 9:00 Registration

9:00 – 9:15 President's Welcome Speech

9:15 – 11:30 Scientific Session 1 – Immunology and Genetics 1

Co-chairs: Ahmet Gül (*Istanbul Univ., Istanbul Faculty of Medicine, Dept. of Internal Medicine, Div. of Rheumatology, Turkey*) and Eun-So Lee (*Dept. of Dermatology, Ajou Univ. School of Medicine, Korea*)

Overview

Ahmet Gül

Istanbul Univ., Istanbul Faculty of Medicine, Dept. of Internal Medicine, Div. of Rheumatology, Turkey

S1-1 GWAS in a heterogenic cohort of Behçet patients: a central role for chromosome 6. A possible association in chromosome 18

Jasper Kappen¹, Jan van Laar¹, Lisette Stolk², Carolina Medina-Gomez³, K Estrada³, Fernando Rivadeneira², Andre Uitterlinden², Graham Wallace⁴, Merih Soyly⁵, Martin van Hagen¹

¹*Internal medicine, section immunology, ErasmusMC Rotterdam, The Netherlands*, ²*Dept. of Internal medicine ErasmusMC Rotterdam*, ³*Dept. of epidemiology ErasmusMC Rotterdam*, ⁴*Dept. of ophthalmology St Thomas Hospital, London*, ⁵*Dept. of Ophthalmology Univ. of Cukurova, School of Medicine, Adana*

S1-2 Susceptibility genes of Behçet's disease and their association with clinical manifestations

Masaki Takeuchi¹, Tatsukata Kawagoe¹, Akira Meguro¹, Masao Ota², Mitsuhiro Takeno³, Yoshiaki Ishigatsubo³, Hidetoshi Inoko⁴, Manabu Mochizuki⁵, Shigeaki Ohno⁶, Nobuhisa Mizuki¹

¹*Dept. Ophthalmology, Yokohama City Univ., Japan*, ²*Dept. Legal Medicine Shinshu Univ.*, ³*Dept. Internal Medicine and Clinical Immunology Yokohama City Univ.*, ⁴*Dept. Molecular Life Science, Div. Molecular Medical Science and Molecular Medicine Tokai Univ.*, ⁵*Dept. Ophthalmology Tokyo Medical and Dental Univ.*, ⁶*Dept. Ophthalmology Hokkaido Univ.*

S1-3 New Genetic Susceptibility Loci and Gene-Gene Interactions in Behçet's Disease

Elaine F Remmers¹, Yohei Kirino¹, George Bertias¹, Yoshiaki Ishigatsubo², Nobuhisa Mizuki³, Ilknur Tugal-Tutkun⁴, Emire Seyahi⁵, Yilmaz Ozyazgan⁶, Akira Meguro⁴, Ahmet Gül⁷, Daniel L Kastner¹

¹*Inflammatory Disease Section, National Human Genome Research Institute, NIH, USA*, ²*Dept. Internal Medicine and Clinical Immunology, Yokohama City Univ.*, ³*Dept. Ophthalmology and Visual Science, Yokohama City Univ.*, ⁴*Istanbul Faculty of Medicine, Dept. Ophthalmology, Istanbul Univ.*, ⁵*Cerrahpasa Faculty of Medicine, Dept. Internal Medicine, Istanbul Univ.*, ⁶*Cerrahpasa Faculty of Medicine, Dept. Ophthalmology, Istanbul Univ.*, ⁷*Istanbul Faculty of Medicine, Dept. Internal Medicine, Div. Rheumatology, Istanbul Univ.*

S1-4 Mechanism of the recruitment of Th17 in the pathogenic process of Behçet's disease


Hidekata Yasuoka¹, Zhu Chen^{1,2}, Tsutomu Takeuchi¹, Masataka Kuwana¹

¹*Internal Medicine/Rheumatology, Keio Univ. School of Medicine, Japan*, ²*Rheumatology and Immunology Anhui Provincial Hospital*

S1-5 REGULATORY T CELLS/TH17 BALANCE IN THE PATHOGENESIS OF PEDIATRIC BEHÇET DISEASE (BD)

Tu-Anh Tran¹, Audrey Hubert², Alexia Letierce³, Benjamin Terrier², Guillaume Geri², David Saadoun^{4,5}, Isabelle Kone-Paut¹, Michelle Rosenzweig²

¹*Dept. of Pediatrics, Pediatric Rheumatology, Bicetre Hospital, Ceremai, Inserm u 1012, Univ. of Paris Sud, France*, ²*Service de Biotherapies/ Upmc Cnrs 7211 Inserm 959 La Pitie Salpetriere Hospital. Paris*, ³*Unite de Recherche Clinique Bicetre Hospital. Univ. of Paris Sud*, ⁴*Dept. of Internal Medicine La Pitie Salpetriere Hospital. Paris*, ⁵*Unit 2. Upmc-Cnrs U7087 La Pitie Salpetriere Hospital. Paris*

**S1-6 Simultaneous production of IL-17 and IFN γ in CD4+ T cells with Behçet's disease**

Jun Shimizu¹, Naruyoshi Fujiwara¹, Fumio Kaneko², Sakae Kaneko³, Noboru Suzuki¹
¹Dept. of Immunology and Medicine, St. Marianna Univ. School of Medicine, Japan, ²Dept. of Dermatology Fukushima Medical Univ., ³Dept. of Dermatology Shimane Univ. School of Medicine

S1-7 Effect of 1,25-Dihydroxyvitamin D3 on Th17 and Th1 cell differentiation in patients with Behçet's disease

Chaokui Wang¹, Yuan Tian¹, Zi Ye¹, Aize Kijlstra², Xiang Xiao¹, Peizeng Yang¹
¹Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical Univ., China, ²Eye Research Institute Maastricht, Dept. of Ophthalmology Univ. Hospital Maastricht

11:50 – 12:50 **Luncheon seminar 1 (3F 301•302)**

Chair: Graham R Wallace (*Centre For Translational Inflammation, Univ. of Birmingham, UK*)

T cells in autoimmune diseases

Kazuhiko Yamamoto
 Dept. of Allergy and Rheumatology, Graduate School of Medicine, The Univ. of Tokyo, Japan
 Co-sponsored by ABBOTT JAPAN CO., LTD./ Eisai Co., Ltd.

Luncheon seminar 2 (3F 311•312)

Chair: Ahmet Gül (*Istanbul Univ., Istanbul Faculty of Medicine, Dept. of Internal Medicine, Div. of Rheumatology, Turkey*)

Recent Progress in Therapeutics for Inflammatory Bowel Disease and Intestinal Behçet's Disease

Toshifumi Hibi
 Dept. of Internal Medicine, School of Medicine, Keio Univ., Japan
 Co-sponsored by Chugai Pharmaceutal Co., Ltd.

13:15 – 15:00 **Scientific Session 2 – Immunology and Genetics 2**

Co-chairs: Kazuya Iwabuchi (*Dept. of Immunology, Kitasato Univ. School of Medicine, Japan*) and Miles R Stanford (*Medical Eye Unit, St Thomas' Hospital, UK*)

S2-1 TLR 2 and TLR4 Splice Variants Expression in Behçet Syndrome Patients

Noha Seoudi¹, Lesley A Bergmeier¹, Eleni Hagi-Pavli¹, David A Bibby², Duncan Clark², Judith Breuer², Michael A Curtis², Farida Fortune¹
¹Centre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, Barts and The London School of Medicine and Dentistry, London, UK, ²Centre for Immunology and Infectious Diseases, Blizard Institute of Cell and Molecular Sciences Barts and The London School of Medicine and Dentistry, London, United Kingdom

S2-2 The sera of patients with Behçets disease and Streptococcus sanguis stimulate membrane expression of hnRNP A2B1 in HDMECs

Sung Bin Cho, Zhenlong Zheng, Do Young Kim, Suhyun Cho, Min Ju Choi, Kwang Hoon Lee, Dongsik Bang
 Dept. of Dermatology and Cutaneous Biology Research Institute, Yonsei Univ. College of Medicine, Seoul, Korea

S2-3 Decreased microRNA-155 expression in ocular Behçet's disease but not in Vogt Koyanagi Harada syndrome

Peizeng Yang¹, Qingyun Zhou¹, Xiang Xiao¹, FuZhen Li¹, Chaokui Wang¹, Yan Zhou¹, Aize Kijlstra²
¹Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical Univ., China, ²Eye Research Institute Maastricht, Dept. of Ophthalmology Univ. Hospital Maastricht

S2-4 Expression of Suppressor of Cytokine Signalling (SOCS) 1 and 3 in Behçets Disease

Mojgan Hamed, Lesley A Bergmeier, Eleni Hagi-Pavli, Farida Fortune
 Clinical and Diagnostic Oral Sciences/Institute of Dentistry, Queen Mary Univ. of London, UK



S2-5 Lymphocyte stress surveillance; a role in Behçets Disease

Graham R Wallace¹, Seema Shafi², Pierre Vantourout², Adrian Hayday², Robert W Vaughan², Ayman Antoun¹, Miles R Stanford²

¹*School of Immunity and Infection, Univ. of Birmingham, Birmingham UK, ²Dept. of Immunology King's College, London*

S2-6 Osteopontin blockade ameliorates experimental autoimmune uveoretinitis model in mice

Kazuya Iwabuchi¹, Daiju Iwata², Masashi Satoh¹, Shigeaki Ohno³, Susumu Ishida², Toshimitsu Uede⁴, Kazunori Onoe⁵

¹*Dept. of Immunology, Kitasato Univ. School of Medicine, Japan, ²Dept. of Ophthalmology Hokkaido Univ. Graduate School of Medicine, ³Dept. of Ocular Inflammation and Immunology Hokkaido Univ. Graduate School of Medicine, ⁴Div. of Molecular Immunology, Institute for Genetic Medicine Hokkaido Univ., ⁵Div. of Immunobiology, Institute for Genetic Medicine Hokkaido Univ.*

S2-7 Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived AGEs formation

Nobuyoshi Kiraichi^{1,2}, Zhenyu Dong³, Daiju Iwata³, Masayoshi Takeuchi⁴, Kenichi Namba³, Kousuke Noda³, Atsuhiko Kanda³, Kazuya Iwabuchi⁵, Sho-ichi Yamagishi⁶, Shigeaki Ohno², Susumu Ishida³

¹*Dept. Ophthalmology, Health Sciences Univ. of Hokkaido, Japan, ²Dept. Ocular Inflamm Immunol Hokkaido Univ. Graduate School of Medicine, ³Dept. Ophthalmology Hokkaido Univ. Graduate School of Medicine, ⁴Dept. Advanced Medicine Kanazawa Medical Univ., ⁵Div. Cellular Immunology Kitasato Univ. School of Medicine, ⁶Dept. Pathophysiology and Therapeutics of Diabetic Vascular Complications Kurume Univ. School of Medicine*

15:00 – 16:30 Poster Presentation and Coffee Break

16:30 – 17:30 **Special lecture**

Chair: Yoshiaki Ishigatsubo (*Dept. Internal Medicine and Clinical Immunology, Yokohama City Univ. Graduate School of Medicine*)

Behçet's Disease in the Post-Genomic Era: Lessons Learned, Unanswered Questions, Exciting Opportunities

Daniel L. Kastner

National Human Genome Research Institute, Bethesda, MD USA

18:00 – 20:00 Banquet in "Pacific" banquet room, InterContinental Yokohama Grand

**Saturday, July 14**

9:00 – 11:30

Scientific Session 3 – Novel treatment (Immunotherapy)

Co-chairs: Ignazio Olivieri (*Rheumatology Dept. of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Italy*) and Jan AM van Laar (*Section of Clinical, Dept. of Immunology and Internal Medicine, Erasmus MC Univ. Medical Center, The Netherland*)

Overview

Nobuhisa Mizuki

Dept. of Ophthalmology and Visual Science, Yokohama City Univ. Graduate School of Medicine, Japan

S3-1 Long term efficacy and safety of Infliximab in the treatment of Behçet's Disease

Pietro Leccese, Angela Padula, Angelo Nigro, Salvatore D'Angelo, Michele Gilio, Carlo Palazzi, Ignazio Olivieri

Rheumatology Dept. of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Italy

S3-2 Effects of Infliximab Therapy in Behçet's Disease

Yuko Takemoto¹, Kenichi Namba¹, Nobuyoshi Kitaichi², Kazuomi Mizuuchi¹, Shigeaki Ohno³, Susumu Ishida¹

¹*Dept. Ophthalmology, Hokkaido Univ. Graduate School of Medicine, Japan,* ²*Dept. Ophthalmology Health Sciences Univ. of Hokkaido,* ³*Dept. Ocular Inflammation and Immunology Hokkaido Univ. Graduate School of Medicine*

S3-3 Serum infliximab levels, baseline TNF-alpha and the effectiveness of infliximab therapy for uveitis in Behçet's disease

Yasushi Inoue¹, Takako Ito², Takahiko Horiuchi¹, Hiroshi Tsukamoto¹, Hiroaki Niiro¹, Yojiro Arinobu¹, Atsunobu Takeda², Takeru Yoshimura², Koh-Hei Sonoda², Tatsuro Ishibashi²

¹*Dept. Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu Univ., Japan,* ²*Dept. Ophthalmology Graduate School of Medical Sciences, Kyushu Univ.*

S3-4 Results of Interferon Alpha 2a (IFN Alpha 2a) Therapy in Patients with Behçet's Disease

Nilufer Yalcindag, Aslihan Uzun

Dept. of Ophthalmology, Ankara Univ., Faculty of Medicine, Turkey

S3-5 How Much Safe is Interferon Treatment in Behçet's Disease?

Burcu Sahin¹, Omer Karadag², Levent Kilic², Ismail Dogan², Metin Isik², Ali Akdogan², Sule Apras Bilgen², Ihsan Ertenli², Sedat Kiraz²

¹*Dept. of Basic Oncology, Hacettepe Univ. Institute of Oncology, Turkey,* ²*Dept. Internal Medicine Div. of Rheumatology Hacettepe Univ. Faculty of Medicine*

S3-6 Cytotoxic drugs in ocular lesions of Behçet Disease (BD). longitudinal study on 20 years

Fereydown Davatchi, Hormoz Shams, Bahar Sadeghi Abdollahi, Farima Ashofteh, Farhad Shahram, Abdolhadi Nadji, Cheyda Chams-Davatchi, Tahereh Faezi, Massoomeh Akhlaghi, Zahra Ghodsi
Behçet Disease Unit, Rheumatology Research Center, Tehran Univ. of Medical Sciences, Iran

S3-7 Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema

Sohee Jeon, Won Ki Lee

Ophthalmology, Seoul Saint Mary's hospital, Korea

S3-8 Therapeutic Role of Isotretinoin in Management of Behçet's Disease: Single Blind Controlled therapeutic study

Khalifa E. Sharquie¹, Raad Muhi Aldeen Helmi², Adil A. Noiami³, Raafa K. Al-Hayani⁴, Mohand A.A. Kadhom⁵

¹*Scientific Council of Dermatology and Venereology, Iraqi Board for Medical Specializations, Iraq,* ²*Dept. of Oral Medicine/College of Dentistry Al-Mustansiriya Univ.,* ³*Dept. of Dermatology/College of Medicine Univ. of Baghdad,* ⁴*Dept. of Dermatology Baghdad Teaching Hospital,* ⁵*Dohuk Specialized Dental Center General Directorate of Health in Dohuk/Kurdistan*



11:50 – 12:50 **Luncheon seminar 3 (3F 301•302)**

Chair: Haner Direskeneli (*Dept. of Rheumatology, Marmara Univ., School of Medicine, Turkey*)

Anti-TNF α therapy for intractable uveoretinitis in Behçet's disease

Shigeaki Ohno

Dept. of Ocular Inflammation and Immunology, Hokkaido Univ. Graduate School of Medicine, Japan

Co-sponsored by Mitsubishi Tanabe Pharma Corporation

Luncheon seminar 4 (3F 311•312)

Chair: Noboru Suzuki (*Dept. of Immunology and Medicine, St. Marianna Univ. School of Medicine, Japan*)

Roles of T lymphocytes in pathogenesis of Behçet's disease

Masataka Kuwana

Div. of Rheumatology Dept. of Internal Medicine, Keio Univ. School of Medicine, Japan

Co-sponsored by Pfizer Japan Inc

13:15 – 15:00 **Scientific Session 4 – Neurological and Vascular lesions**

Co-chairs: Shunsei Hirohata (*Dept. of Rheumatology and Infectious Diseases, Kitasato Univ. School of Medicine, Japan*) and Jorge Crespo (*Coimbra Univ. Hospital, Portugal*)

S4-1 Transverse Myelitis in Patients with Behçets Disease: A series of four cases

Berivan Bitik

Dept. of Rheumatology, Gazi Univ., Ankara, Turkey

S4-2 Cyclosporine-related and cyclosporine-unrelated acute neurological events in Behçet's disease

Shunsei Hirohata¹, Hirotohi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Masataka Kuwana⁵, Mitsuhiro Takeno⁶, Yoshiaki Ishigatsubo⁶

¹*Dept. Rheumatology and Infectious Diseases, 1Kitasato Univ. of School of Medicine, Japan, 2Dept. Internal Medicine 2Teikyo Univ. School of Medicine, 3Dept. Internal Medicine 33Tokyo Medical Univ. School of Medicine, 4Dept. Internal Medicine 4St Marianna Univ. School of Medicine, 5Dept. Internal Medicine Keio Univ. School of Medicine, 6Dept. Internal Medicine and Clinical Immunology Yokohama City Univ. Graduate School of Medicine*

S4-3 Arterial CNS involvement in Behçet disease

Gulsen Akman-Demir¹, Erkingul Shugaiv², Murat Kurtuncu³, Melike Mutlu², Nilufer Yesilot², Erdem Tuzun², Oguzhan Coban², Sara Bahar²

¹*Istanbul Bilim Univ., Dept. of Neurology, Turkey, 2Istanbul Univ., Istanbul Faculty of Medicine Dept. of Neurology, 3Acibadem Univ. Dept. of Neurology*

S4-4 VASCULAR INVOLVEMENT IN PATIENTS WITH BEHÇET'S SYNDROME

Koray Tascilar², Melike Melikoglu², Serdal Ugurlu², Erkan Caglar¹, Emire Seyahi²

¹*Dept. of Rheumatology, Istanbul Univ. Cerrahpasa Medical Faculty, Turkey, 2Dept. of Rheumatology Istanbul Univ. Cerrahpasa Medical Faculty*

S4-5 Clinical features of Vasculo- Behçet's disease in Japan

Haruko Ideguchi¹, Akiko Suda², Reikou Watanabe³, Masataka Kuwana⁴, Hirotohi Kikuchi⁵, Hiroko Nagafuchi⁶, Kazuyoshi Saito⁷, Shunsei Hirohata⁸, Mitsuhiro Takeno³, Yoshiaki Ishigatsubo³

¹*Center for Rheumatic Diseases, Yokohama City Univ. Medical Center, Japan, 2Dept. of Rheumatology Yokohama Minami Kyouzai Hospital, 3Dept. of Internal Medicine and Clinical Immunology Yokohama City Univ. Graduate School of Medicine, 4Dept. of Internal Medicine Keio Univ. School of Medicine, 5Dept. of Microbiology and Immunology Teikyo Univ. School of Medicine, 6Dept. of Internal Medicine St. Marianna Univ. School of Medicine, 7The First Dept. of Internal Medicine School of Medicine, Univ. of Occupational and Environmental Health, 8Dept. of Rheumatology and Infectious Diseases Kitasato Univ. School of Medicine*

S4-6 MR imaging of vein wall thickness in noraml subjects and patients with Behçets Syndrome

Iain T Pierce¹, Peter D Gatehouse¹, Nicola Ambrose², Dorian O Haskard², David N Firmin¹

¹*CMR Unit, Royal Brompton Hospital, NHLI, Imperial College London, UK, 2Cardiovascular Sciences, NHLI*



Imperial College London

S4-7 Abdominal Aortic Aneurysms in Behçet's Disease: Investigation of the Disease Course with Findings of 10 Patients

Tuncay Sahutoglu¹, Burak Erer¹, Bahar Artim-Esen¹, Murat Aksoy², Arzu Poyanli³, Ahmet Gül¹
¹Dept. of Internal Medicine, Div. of Rheumatology, Istanbul Univ., Istanbul Faculty of Medicine, Turkey, ²Dept. of Surgery Istanbul Univ., Istanbul Faculty of Medicine, Turkey, ³Dept. of Radiology Istanbul Univ., Istanbul Faculty of Medicine, Turkey

15:00 – 16:30 Poster Presentation and Coffee Break

16:30 – 17:30 Scientific Session 5 – Assessment of disease activity (Epidemiology)

Co-chairs: Fumio Kaneko (*Institute of Dermato-Immunology and Allergy, Southern TOHOKU Research Institute for Neuroscience, Japan*) and Dongsik Bang (*Dept. of Dermatology, Yonsei Univ. College of Medicine, Korea*)

Overview

Mitsuhiro Takeno

Dept. of Internal Medicine and Clinical Immunology, Yokohama City Univ. Graduate School of Medicine, Japan

S5-1 Behçet's Disease (BD) in IRAN. Analysis of 6832 patients

Fereydoun Davatchi, Farhad Shahram, Cheyda Chams-Davatchi, Abdolhadi Nadji, Hormoz Shams, Massoomeh Akhlaghi, Tahereh Faezi, Zahra Ghodsi, Bahar Sadeghi Abdollahi, Farima Ashofteh
Rheumatology Research Center, Tehran Univ. of Medical Sciences, Iran

S5-2 PED-BD, COHORT STUDY FOR PAEDIATRIC BEHÇET'S DISEASE: REPORTING 206 PATIENTS

Isabelle Kone-Paut¹, Martha Darce Bello¹, Farhad Shahram², Seza Ozen³, Rolando Cimaz⁴, Michael Hofer⁵, Bouchra Chkirate⁶, Kenza Bouayed⁷, Marco Gattorno⁸, Jordi Anton⁹, Tu-Anh Tran¹
¹Pediatric Rheumatology, Bicetre Univ. Hospital, France, ²Rheumatology Research Center Shariati Hospital Iran, ³Pediatrics Hacettepe Univ. Ankara, ⁴Pediatric Rheumatology Meyer Institut Firenze Italy, ⁵Pediatric Rheumatology Vaudois Univ. Hospital Switzerland, ⁶Pediatrics Rabat Univ. Hospital, ⁷Pediatrics IBN Rochid Univ. Hospital, ⁸Pediatric Rheumatology G. Gaslini Institut. Genoa, ⁹Pediatric Rheumatology S Joan de Deu Univ. Hospit

S5-3 Assesment of disease activity in Behçet disease: comparison of BDCAF, BSAS and RAPID3 scores: extended report

Sedat YILMAZ¹, Ismail SIMSEK¹, Muhammet CINAR¹, Hakan ERDEM¹, Osman KOSE², Yusuf YAZICI³, Salih PAY¹

¹Div. of Rheumatology, Gulhane School of Medicine, Turkey, ²Dept. of Dermatology Gulhane School of Medicine, ³Div. of Rheumatology New York Univ. Hospital for Joint Diseases

17:30 – 19:30 General Assembly


Memorial Presentation for the Local President Award

HOW MUCH DOES THE EVALUATION OF THE DEMOGRAPHIC FACTORS AND INITIAL CLINICAL MANIFESTATIONS HELP TO PREDICT PROGNOSIS OF BEHÇET DISEASE?

Nihat Dilsen, Meral Konice, Orhan Aral, Lale Ocal, Murat Inanc, Ahmet Gül

Dept. of Internal Medicine, Div. of Rheumatology, Istanbul Univ., Istanbul Faculty of Medicine, Turkey

Saturday, July 14th

**Sunday, July 15**

9:00 – 10:15

Scientific Session 6 – Ocular and mucocutaneous lesions

Co-chairs: Gonca Mumcu (*Dept. of Health Informatics and Technologies, Faculty of Health Sciences, Marmara Univ., Turkey*) and Hyeong-Gon Yu (*Dept. of Ophthalmology, Seoul National Univ., Korea*)

S6-1 FIVE-YEAR FOLLOW-UP ORAL HEALTH DATA IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY

Gonca Mumcu¹, Nevsun Inanc², Nur Sisman³, Tulin Ergun⁴, Haner Direskeneli²

¹*Faculty of Health Sciences, Dept. of Health Informatics and Technologies, Marmara Univ., Turkey*, ²*School of Medicine, Dept. of Rheumatology, Marmara Univ., Istanbul*, ³*Faculty of Health Sciences, Dept. of Health Systems Management, Marmara Univ., Istanbul*, ⁴*School of Medicine, Dept. of Dermatology, Marmara Univ., Istanbul*

S6-2 Frequent oral ulceration during early disease may increase the risk of organ involvement in men with Behçet's syndrome

Vedat Hamuryudan¹, Gulen Hatemi¹, Necdet Sut², Serdal Ugurlu¹, Sebahattin Yurdakul¹, Hasan Yazici¹
¹*Div. of Rheumatology, Cerrahpasa Medical Faculty, Istanbul Univ., Turkey*, ²*Dept. of Biostatistics, Trakya Medical Faculty Edirne Univ.*

S6-3 Is non-oral aphthosis Behçet disease associated with more ocular involvement?

Seyedeh Tahereh Faezi, Pedram Paragomi, Farhad Shahram, Abdolhadi Nadji, Maassoumeh Akhlaghi, Ahmad Reza Jamshidi, Bahar Sadeghi Abdollahi, Roghayeh Larimi, Farima Ashofteh, Fereydoun Davatchi
Rheumatology Research Center (RRC), Tehran Univ. of Medical Sciences (TUMS), Iran

S6-4 Correlation between development of antinuclear antibody titre and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab

Kenichi Namba¹, Daiju Iwata¹, Kazuomi Mizuuchi¹, Nobuyoshi Kitaichi^{2,3}, Satoru Kase¹, Yuko Takemoto¹, Shigeaki Ohno³, Susumu Ishida¹

¹*Dept. Ophthalmology, Hokkaido Univ. Graduate School of Medicine, Japan*, ²*Dept. Ophthalmology Health Sciences Univ. of Hokkaido*, ³*Dept. Ocular Inflammation and Immunology Hokkaido Univ. Graduate School of Medicine*

S6-5 Patterns of Behçet Uveitis in Turkey: the First National Registry (BUST Study) Report

Nilufer Yalcindag¹, Ilknur Tugal-Tutkun², Yilmaz Ozyazgan³, Figen Batioglu¹, Haluk Kazokoglu⁴

¹*Dept. of Ophthalmology, Ankara Univ. Faculty of Medicine, Turkey*, ²*Dept. of Ophthalmology Istanbul Univ., Istanbul Faculty of Medicine*, ³*Dept. of Ophthalmology Istanbul Univ., Cerrahpasa Faculty of Medicine*, ⁴*Dept. of Ophthalmology Marmara Univ. Faculty of Medicine, Turkey*

10:15 – 11:30

Scientific Session 7 – Intestinal lesions

Co-chairs: Mamoru Watanabe (*Dept. of Gastroenterology and Hepatology, Tokyo Medical and Dental Univ., Japan*) and Gulen Hatemi (*Istanbul Univ., Cerrahpasa Medical School, Dept. of Internal Medicine, Div. of Rheumatology, Turkey*)

Overview**Diagnosis and therapeutic strategy for Intestinal Behçet disease**

Makoto Naganuma

Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio Univ., Japan

S7-1 Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behçet's Syndrome: Experience in A Dedicated Center

Ibrahim Hatemi¹, Gulen Hatemi², Yusuf Erzin¹, Aykut Ferhat Celik¹, Hasan Yazici²

¹*Dept. Internal Medicine, Gastroenterology, Istanbul Univ. Cerrahpasa Medical School, Turkey*, ²*Dept. Internal Medicine, Rheumatology Istanbul Univ. Cerrahpasa Medical School*

S7-2 ANTI-SACCHAROMYCES CEREVISAE ANTIBODIES (ASCA) IN ACTIVE BEHÇET'S DISEASE: A MARKER OF INTESTINAL INVOLVEMENT?

Leandro Lara Prado, Kristopherson Lustosa Augusto, Patricia Fernandes Magalhaes, Vilma Trindade Viana, Carla G S Saad, Celio Roberto Goncalves

Rheumatology Div., Faculdade de Medicina da Universidade de Sao Paulo, Brasil




S7-3 Study on the safety and efficacy of Infliximab (IFX), an anti-TNF-alpha antibody, in patients with refractory intestinal-Beçet's disease (BD)

Kazuyoshi Saito, Ippei Miyagawa, Shigeru Iwata, Masao Nawata, Yoshiya Tanaka
The First Dept. of Internal Medicine, School of Medicine, Univ. of Occupational and Environmental Health, Japan

S7-4 The efficacy of Infliximab therapy for intestinal Beçet's disease: the retrospective study in Japan

Reikou Watanabe¹, Mitsuhiro Takeno¹, Masakazu Nagahori², Michiko Kurosawa³, Ritei Uehara⁴, Masaki Nagai⁵, Yoshiaki Ishigatsubo¹
¹Dept. of Internal Medicine and Clinical Immunology, Yokohama City Univ. Graduate School of Medicine, Japan, ²Dept. of Advanced Therapeutics for GI Diseases Tokyo Medical and Dental Univ., ³Dept. of Epidemiology and Environmental Health Juntendo Univ. School of Medicine, ⁴Dept. of Public Health Jichi Medical Univ., ⁵Dept. of Public Health, Faculty of Medicine Saitama Medical Univ.

11:30 – 12:00 Closing remarks



POSTER PROGRAM

(Friday, July 13)

Poster Session 1 Immunology and Genetics

P1-1-001 Behçet's Disease and HLA A26

Zemfira S Alekberova, M Krylov, Regina Goloeva, J Guseva, Evgenii L Nasonov
Research Institute of Rheumatology, Moscow, Russia

P1-1-002 Correlation between plasma homocysteine level and HLA-B51 in patients with Behçet's disease and control group

Farhad Shahram, Sorayya Shademan-far, Abdolhadi Nadji, Maassomeh Akhlaghi, Seyedeh Tahereh Faezi, Bahar Sadeghi-Abdollahi, Alireza Faridar, Fereydoun Davatchi
Rheumatology Research Center, Tehran Univ. of Medical Sciences, Iran

P1-1-003 IL23R GENE POLYMORPHISM IS ASSOCIATED WITH BEHÇET'S DISEASE IN A SECOND COHORT IN TURKEY

Ayca Duman¹, Vusale Abbasova¹, Fatma Alibaz-Oner², Vuslat Yilmaz⁴, Tulin Ergun³, Haner Direskeneli², Guher Saruhan-Direskeneli⁴
¹*Istanbul School of Medicine, Turkey*, ²*Istanbul School of Medicine*, ³*Marmara School of Medicine*, ⁴*Istanbul School of Medicine*, ⁵*Marmara School of Medicine*, ⁶*Marmara School of Medicine*, ⁷*Istanbul School of Medicine*

P1-1-004 Association study of IL10 and IL23R-IL12RB2 in Iranian Behçet's disease patients

Joana M. Xavier^{1,2}, Farhad Shahram³, Fereydoun Davatchi³, Jorge Crespo⁴, Bahar S. Abdollahi³, Gorete Jesus⁵, Jose V. Pato⁶, Niloofar M. Shafiee³, Fahmida Ghaderibarim³, Sofia A. Oliveira^{1,2}
¹*Instituto de Medicina Molecular, Faculdade de Medicina da Univ.ersidade de Lisboa, Portugal*, ²*Instituto Gulbenkian de Ciencia Oeiras, Portugal*, ³*Rheumatology Research Center Tehran Univ. of Medical Sciences, Tehran, Iran*, ⁴*Centro Hospitalar e Univ.ersitario de Coimbra Portugal*, ⁵*Hospital Infante D. Pedro Aveiro, Portugal*, ⁶*Instituto Portugues de Reumatologia Lisboa, Portugal*

P1-1-005 Targeted deep re-sequencing implicates rare and low frequency coding variants in IL23R, MEFV, TLR4, and NOD2 in Behçet's disease

Yohei Kirino^{1,2}, Qing Zhou¹, Yoshiaki Ishigatsubo², Nobuhisa Mizuki³, Ilknur Tugal-Tutkun⁴, Emire Seyahi⁵, Yilmaz Ozyazgan⁶, Akira Meguro⁴, Daniel L Kastner¹, Ahmet Gül⁷, Elaine F Remmers¹
¹*Inflammatory Disease Section, National Human Genome Research Institute, NIH, USA*, ²*Dept. Internal Medicine and Clinical Immunology Yokohama City Univ.*, ³*Dept. Ophthalmology and Visual Science Yokohama City Univ.*, ⁴*Istanbul Faculty of Medicine, Dept. Ophthalmology Istanbul Univ.*, ⁵*Cerrahpasa Faculty of Medicine, Dept. Internal Medicine Istanbul Univ.*, ⁶*Cerrahpasa Faculty of Medicine, Dept. Ophthalmology Istanbul Univ.*, ⁷*Istanbul Faculty of Medicine, Dept. Internal Medicine, Div. Rheumatology Istanbul Univ.*

P1-1-006 XBP1 SPLICING AND REDUCED XBP1 EXPRESSION IN BEHÇET'S DISEASE


Neslihan Abaci¹, Fulya Cosan¹, Hulya Azakli¹, Sema Sirma-Ekmekci¹, Zeliha Emrence¹, Aris Cakiris¹, Micheal J Ombrello², Duran Ustek¹, Ahmet Gül^{1,3}
¹*Dept. of Genetics, Institute for Experimental Medical Research, Istanbul Univ., Turkey*, ²*The Inflammatory Disease Section National Human Genome Research Institute, Bethesda, United States*, ³*Div. of Rheumatology, Dept. of Internal Medicine Istanbul Faculty of Medicine, Istanbul Univ., Turkey*

P1-1-007 Analysis of interleukin 17A single nucleotide polymorphism in Behçet's Disease

Koichiro Nakamura¹, Fumio Kaneko², Akira Meguro³, Nobuhisa Mizuki³
¹*Dept. Dermatology, Saitama Medical Univ., Japan*, ²*Skin Unit Southern Tohoku General Hospital*, ³*Dept. Ophthalmology Yokohama City Univ.*

P1-1-008 TIR-domain-containing adaptor protein gene TIRAP S180L polymorphism in Behçet's disease

Gorkem Turunc¹, Doga Coskun¹, Fatma Alibaz-Oner², Sibel P Yentur¹, Tulin Ergun³, Haner Direskeneli², Guher Saruhan-Direskeneli¹
¹*Dept. of Physiology, I.U. Istanbul Medical Faculty, Turkey*, ²*Dept. of Rheumatology Internal Medicine Marmara Medical School*, ³*Dept. of Dermatology Marmara Medical School*

**P1-1-009 Targeted sequencing of candidate genes in Behçet's Disease**Hyeong Gon Yu¹, Sang Jin Kim¹, Hee Yoon Cho², Jae Suk Kim³, Hum Chung¹¹Dept. of Ophthalmology, Seoul National Univ. College of Medicine & Medical Research Center, Seoul National Univ., Korea, ²Dept. of Ophthalmology Hanyang Univ. College of Medicine, ³Dept. of Ophthalmology Inje Univ., Sanggye Paik Hospital**P1-1-010 Expression and function of inducible costimulator on peripheral blood CD4 T cells in patients with ocular Behçets disease: a new activity marker?**Yoshihiko Usui^{1,3}, Masaru Takeuchi², Takeshi Kezuka¹, Yoko Okunuki¹, Hisaya Akiba³, Hiroshi Goto¹¹Ophthalmology, Tokyo Medical Univ. Hospital, Japan, ²Ophthalmology National Defense Medical College, ³Immunology Juntendo Univ. School of Medicine**P1-1-011 Role of TGFbeta/Smad pathway in T cell functions in patients with Behçet's disease**Jun Shimizu¹, Naruyoshi Fujiwara¹, Fumio Kaneko², Sakae Kaneko³, Noboru Suzuki¹¹Dept. of Immunology and Medicine, St. Marianna Univ. School of Medicine, Japan, ²Dept. of Dermatology Fukushima Medical Univ., ³Dept. of Dermatology Shimane Univ. School of Medicine**P1-1-012 The B or not the B?A study into the role of the B-cell in Behçets disease**Tim B. van der Houwen^{1,2}, Jasper H. Kappen¹, Lieke S.J. Kamphuis^{1,2}, Paul L.A. van Daele^{1,2}, Martin van Hagen^{1,2}, Menno C. van Zelm², Jan A.M. van Laar^{1,2}¹Dept. Internal Medicine, section Clinical Immunology, ErasmusMC Rotterdam, The Netherlands, ²Dept. Immunology ErasmusMC Rotterdam**P1-1-013 Selective accumulation of gamma-delta T lymphocytes and B B1 cells in anterior chamber of eye in Behçets disease**

Tigran Davtyan, Anna Hovakimyan


"Armenicum" Investigation Center, Malayan Eye Center, Yerevan, Armenia

Poster Session 2 Uveitis and threapy**P2-1-027 DEMOGRAPHIC, GENETIC AND CLINICAL FEATURES OF OCULAR INVOLVEMENTS IN BEHÇET'S DISEASE IN TUNISIA**

Thouraya Ben Salem, Fatma Said, Monia Khanfir, Amira Hamzaoui, Amel Braham, Mounir Lamloum, Imed Ben Ghorbel, Habib M Houman

Dept. Internal Medicine, La Rabta Univ. Hospital, Tunisia

P2-1-028 Characteristics of ocular involvement in Behçet's diseaseRegina Georgievna Goloeva¹, Vladimir Eduardovich Tankovskiy², Zemfira Saddulaevna Alekberova¹¹Research Institute of Rheumatology Russian Academy Medical Science, Moscow, Russia, ²Moscow Helmholtz Research Institute of Eye Diseases**P2-1-029 Interpretation of ophthalmic photographs for the diagnosis of Behçet uveitis**Ilknur Tugal-Tutkun¹, Sumru Onal², Yilmaz Ozyazgan³, Merih Soylu⁴¹Dept. of Ophthalmology, Istanbul Univ., Istanbul Faculty of Medicine, Turkey, ²Dept. of Ophthalmology VK Foundation American Hospital, Istanbul, ³Dept. of Ophthalmology Istanbul Univ., Cerrahpasa Medical School, ⁴Dept. of Ophthalmology Cukurova Univ., Faculty of Medicine**P2-1-030 Serum Vitronectin Levels in Patients with Behçet's Disease**Ali Yalcindag¹, Aslihan Uzun², Nilufer Yalcindag², Yesim Gedik Oguz², Namik Delibas¹¹Dept. of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital, Turkey, ²Dept. of Ophthalmology Ankara Univ., Faculty of Medicine**P2-1-031 Alpha-enolase expression on the surfaces of monocytes in patients with Behçet and non-Behçet uveitis**Tae Wan Kim^{1,2}, Jae Seung Kang³, Jeeyun Ahn^{1,2}, Hum Chung², Hyeong Gon Yu²¹Dept. Ophthalmology, Seoul Metropolitan Government Seoul National Univ. Boramae Medical Center, Korea, ²Dept. Ophthalmology Seoul National Univ., College of Medicine, ³Dept. Anatomy and Tumor Immunity Medical Research Center Seoul National Univ., College of Medicine

**P2-1-032 Detection of toll like receptors in Behçets disease with uveitis following infliximab treatment**

Takeshi Kezuka, Yoshihiko Usui, Yoko Okunuki, Naoyuki Yamakawa, Hiroshi Goto
Dept. of Ophthalmology, Tokyo Medical Univ., Japan

P2-1-033 Low vision care needs of patients with Behçet's disease

Tomomi Nishida¹, Akiko Yamada^{1,2}, Mayumi Komatsu^{1,2}, Yuki Nishiwaki^{1,2}, Marie Miwa^{1,2},
Tsutomu Nakanishi², Akio Kubo², Satoshi Nakadomari^{1,2}

¹*Dept. Medical Treatment (2), Ophthalmology, Hospital, National Rehabilitation Center for Persons with Disabilities, Japan,* ²*Dept. of Rehabilitation, Low Vision Training Hospital, National Rehabilitation Center for Persons with Disabilities*

P2-1-034 INFLIXIMAB THERAPY FOR UVEITIS IN BEHÇET' DISEASE

Kayo Terauchi¹, Takeaki Uehara¹, Ryusuke Yoshimi¹, Atsushi Ihata¹, Atsuhisa Ueda¹, Etsuko Shibuya²,
Nobuhisa Mizuki², Yoshiaki Ishigatsubo¹

¹*Dept. Internal Medicine and Clinical Immunology, Yokohama City Univ. Graduate School of Medicine, Japan,* ²*Yokohama City Univ. Graduate School of Medicine Dept. Ophthalmology*

P2-1-035 Clinical efficacy of infliximab in patients with Behçet's disease

Takuma Wada, Yuji Akiyama, Kojiro Sato, Yu Funakubo, Toshihide Mimura
Dept. Rheumatology and Applied Immunology, Saitama Medical Univ., Japan

Poster Session 3 Mucocutaneous lesion**P3-1-046 Iron deficiency state in resistant oral aphthosis of Behçet's disease**

Farhad Shahram, Taraneh Dormohammadi Toosi, S. Zahra Ghodsi, Abdolhadi Nadji,
Arash Tehrani Banihashemi, Roghieh Larimi, Fereydoun Davatchi, Cheyda Chams-Davatchi
Rheumatology Research Center, Tehran Univ. of Medical Sciences, Iran

P3-1-047 Fibromyalgia in Behçet disease is associated with disease activity.

Meryem Can¹, Fatma Alibaz-Oner¹, Sibel Yilmaz-Oner¹, Nevsun Inanc¹, Tulin Ergun², Gonca Mumcu³,
Haner Direskeneli¹

¹*Dept. of Rheumatology, School of Medicine, Marmara Univ., Istanbul, Turkey,* ²*Dept. of Dermatology, School Of Medicine, Marmara Univ., Istanbul, Turkey,* ³*Faculty of Health Sciences, Dept. of Health Informatics and Technologies Marmara Univ., Istanbul, Turkey*

P3-1-048 Quality of life and fatigue in patients with Behçet disease

Meryem Can¹, Fatma Alibaz-Oner¹, Birkan Ilhan¹, Sibel Yilmaz-Oner¹, Nevsun Inanc¹, Tulin Ergun²,
Gonca Mumcu³, Haner Direskeneli¹

¹*Dept. of Rheumatology, School of Medicine, Marmara Univ., Istanbul, Turkey,* ²*Dept. of Dermatology, School Of Medicine Marmara Univ., Istanbul, Turkey,* ³*Faculty of Health Sciences, Dept. of Health Informatics and Technologies Marmara Univ., Istanbul, Turkey*

P3-1-049 Is Oral Aphthosis of Behçet Disease (BD) different from Idiopathic Recurrent Aphthous Stomatitis (RAS)

Bahar Sadeghi Abdollahi, Fereydoun Davatchi, Cheyda Chams-Davatchi, Zahra Ghodsi, Farhad Shahram,
Abdolhadi Nadji, Tahereh Faezi, Massoomeh Akhlaghi, Farima Ashofteh, Mostafa Ghorbani
Rheumatology Research Center, Tehran Univ. of Medical Sciences, Iran

P3-1-050 THE STATUS OF SERUM VITAMIN D IN PATIENTS WITH RECURRENT APHTHOUS COMPARED WITH CONTROLS

Sousan Kolahi^{1,2}, Alireza Khabbazi^{1,2}, Mehrzad Hajjaliloo^{1,2}, Sakinehkhataoun Sharif^{1,2}, Zahra Jalali¹

¹*Internal Medicine Dept./Tabriz Univ. of Medical Sciences, Iran,* ²*Rheumatology Research Team, Tabriz Univ. of Medical Sciences*

P3-1-051 Fatigue Is An Important Problem in Patients with Behçet's Syndrome

Deram Buyuktas¹, Gulen Haremi², Sukran Yuksel-Findikoglu², Koray Tascilar², Serdal Ugurlu²,
Sebahattin Yurdakul²

¹*Dept. Internal Medicine, Istanbul Univ. Cerrahpasa Medical School, Turkey,* ²*Dept. Internal Medicine, Rheumatology, Istanbul Univ. Cerrahpasa Medical School*

**P3-1-052 Therapeutic Role of Isotretinoin in Management of Recurrent Aphthous Stomatitis: Single Blind Controlled therapeutic study**

Khalifa E. Sharquie¹, Raad Muhi Aldeen Helmi², Adil A. Noiami³, Raafa K. Al-Hayani⁴, Mohand A.A. Kadhom⁵

¹Scientific Council of Dermatology and Venereology, Iraqi Board for Medical Specializations, Iraq, ²Dept. of Oral Medicine/College of Dentistry, Al-Mustansiriya Univ., ³Dept. of Dermatology/College of Medicine, Univ. of Baghdad, ⁴Dept. of Dermatology, Baghdad Teaching Hospital, ⁵Dohuk Specialized Dental Center, General Directorate of Health in Dohuk/Kurdistan

Poster Session 4 Neurological, vascular, and intestinal involvement**P4-1-064 Study of colonoscopic findings in intestinal Behçet's disease in Egyptian patients**

Mohamed Nabil Rafat Farahat¹, Mohamed Ibraheim Yousef¹, Mahmoud Mosa Bazeed¹, Mohamed Noshay El-Alfy¹, Ibraheim Hasan Mohamed²

¹Dept. Internal Medicine, Faculty of Medicine, Al-Azhar Univ., Cairo, Egypt., ²Dept. Pathology Faculty of Medicine, Al-Azhar Univ., Cairo, Egypt.

P4-1-065 The clinical course and treatment in patients with intestinal Behçet's disease; a single center experience of current 30 cases

Yoshitaka Kimura¹, Kurumi Asako¹, Hirotooshi Kikuchi², Akiteru Takeuchi¹, Hajime Kouno¹

¹Dept. of Internal Medicine, Teikyo Univ. School of Medicine, Japan, ²Dept. of Microbiology and Immunology, Teikyo Univ. School of Medicine

P4-1-066 Efficacy and Safety of Infliximab in Intestinal Behçet's Disease

Hiroto Kinoshita¹, Reiko Kunisaki¹, Hisae Yamamoto¹, Reikei Matsuda¹, Machiko Nakatogawa¹, Hideaki Kimura¹, Katsuaki Tanaka², Shin Maeda³

¹Inflammatory Bowel Disease Center, Yokohama City Univ. Medical Center, Japan, ²Gastroenterology Center, Yokohama City Univ. Medical Center, ³Dept. of Gastroenterology, Yokohama City Univ.

P4-1-067 NEUROLOGICAL INVOLVEMENT IN BEHÇETS DISEASE: DEMOGRAPHIC, CLINICAL AND GENETIC FEATURES IN 121 TUNISIAN PATIENTS.

Thouraya Ben Salem, Nabil Bel Feki, Amira Hamzaoui, Monia Khanfir, Mounir Lamloum, Amel Braham, Imed Ben Ghorbel, Habib M Houman

Dept. Internal Medicine, La Rabta Univ. Hospital, Tunisia

P4-1-068 Neuropsychiatric involvement in Behçet s disease. Monocentric study of 43 patients.

Zoubida Tazi Mezalek, Hind Charadi, Wafa Ammouri, Hicham Harmouche, Mouna Maamar, Mohamed Adnaoui, Mohamed Aouni

Internal medicine Dept., Ibn Sina hospital - Rabat - Morocco

P4-1-069 Pseudotumor cerebri as a presenting sign of Behçet Disease

Gulden Akdal¹, Aylin Yaman², Meltem Soylev Bajin², Suleyman Men³, Gulsen Akman Demir⁴

¹Dokuz Eylul Univ. Hospital Dept. of Neurology and Neurosciences, Turkey, ²Dokuz Eylul Univ. Hospital Dept. of Ophthalmology, ³Dokuz Eylul Univ. Hospital Dept. of Radiology, ⁴Istanbul Bilim Univ. Dept. of Neurology

P4-1-070 Cerebral white matter lesions in Behçet disease: neuro-Behçet or multiple sclerosis?

Gulsen Akman-Demir¹, Melike Mutlu², Asli Kiyat-Atamer¹, Erkingul Shugaiv², Murat Kurtuncu⁴, Ilknur Tugal-Tutkun³, Erdem Tuzun², Sara Bahar²

¹Istanbul Bilim Univ., Dept. of Neurology, Turkey, ²Istanbul Univ., Istanbul Faculty of Medicine Dept. of Neurology, ³Istanbul Univ., Istanbul Faculty of Medicine Dept. of Ophthalmology, ⁴Acibadem Univ., Dept. of Neurology

P4-1-071 Restless legs syndrome in neuro Behçet's disease

Mine Hayriye Sorgun, Canan Yucesan

Dept. Neurology, Ankara Univ. School of Medicine, Turkey